Terazosin Hydrochloride Capsules

This product is a selective α1 receptor blocker that can reduce peripheral vascular resistance and has a hypotensive effect on both systolic and diastolic blood pressure. It is usually not accompanied by tachycardia, has no adverse effects on electrolytes, blood sugar, liver and kidney function, and has a certain improvement effect on blood lipids. This product also has the effect of relaxing bladder and prostate smooth muscles, and can relieve symptoms such as dysuria caused by benign prostatic hypertrophy.

The main ingredient of this product is terazosin hydrochloride

This product is a hard capsule, and the contents are white or off-white granules.

1. Used to treat hypertension, and can be used alone or in combination with other antihypertensive drugs. 2. Used to improve urination symptoms in patients with benign prostatic hyperplasia, such as frequent urination, urgency, thinning of the urine stream, difficulty urinating, increased nocturia, and a feeling of incomplete urination.

Oral. Once a day, the starting dose is 1 mg, and the first dose is taken before bedtime. If you need to take this product again after stopping the drug, you must also start from 1 mg and gradually increase the dose. Hypertension: The common dose is 1-10 mg per day, and the maximum dose is 20 mg per day. The dose is gradually increased until a satisfactory effect is achieved. Benign prostatic hyperplasia: Once a day, 2 mg each time, taken before bedtime every night.

The main adverse reactions of this product are: headache, dizziness, weakness, palpitations, nausea, postural hypotension, etc. These reactions are usually mild and can disappear on their own with continued treatment. The dosage can be reduced if necessary.

It is contraindicated for those who are allergic to this product.

Precautions for children: The safety and effectiveness of this product for children have not been determined. Precautions for pregnancy and lactation: In a study conducted before and after delivery in rats, the mortality rate of young rats in the group given a dose of 120 mg/(kg·day) (75 times the maximum recommended dose for humans) was significantly higher than that in the control group within 3 weeks after delivery. It is not clear whether terazosin is secreted in breast milk. Because many drugs are secreted in breast milk, care should be taken when terazosin is given to lactating women. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

In controlled trials, terazosin was added to diuretics and certain beta-adrenergic blockers, and no unexpected interactions were observed. Terazosin has been co-administered with the following classes of drugs: analgesics/anti-inflammatory drugs, antibiotics, anticholinergic/sympathomimetic drugs, antigout drugs, cardiovascular drugs, corticosteroids, gastrointestinal drugs, hypoglycemic drugs, sedatives and tranquilizers. When terazosin and verapamil are co-administered with other drugs, the mean AUC0-24 of terazosin increases by 11% at the first administration of verapamil and by 24% after 3 weeks of treatment with verapamil, and the mean Tmax of terazosin decreases from 1.3 hours to 0.8 hours at this time. No significant effect on verapamil was found. When terazosin is co-administered with captopril to reach steady state, the maximum plasma concentration of terazosin increases linearly with dose.

Keep in a sealed container and shield from light. The validity period is tentatively set at two years.

2mg

24 months

Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

• Founded in:

  2001-06-22

• Address:

  No. 118, Huagong Road, Dongtou District, Wenzhou

• Tax NO.:

  913303007303249630

• Registered Funds:

  327.30432 million yuan

• Website:

  Log in to view

• Email:

  Log in to view